Navigation Links
Commercial Launch of Lexiscan(TM) (Regadenoson) Injection Triggers $10 Million Milestone Payment from TPG-Axon Capital to CV Therapeutics
Date:6/24/2008

te prescribing information for Lexiscan(TM) is available at http://www.Lexiscan.com.

About Myocardial Perfusion Imaging Studies

MPI studies help detect and characterize coronary artery disease by identifying areas of poor blood flow in the heart. Every year, between 7.5 and 9.3 million MPI studies are performed in the United States. Almost half of these studies utilized a pharmacologic stress agent.

About TPG-Axon Capital

TPG-Axon Capital is a leading global investment firm, with over $16 billion of capital invested in both public and private markets around the world. Through offices in New York, London, Hong Kong and Tokyo, the firm makes focused, long-term investments in companies, industries and assets across geographies.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved products include Ranexa(R) (ranolazine extended-release tablets), indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and Lexiscan(TM) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. CV Therapeutics also has other clinical and preclinical drug development candidates and programs that have not been determined to be safe or effective in humans for any uses.

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subje
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
2. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
3. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
4. ADVENTRX Appoints Vice President of Commercialization
5. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
6. Accera, Inc. Names William T. Poncy Vice President of Commercial Development
7. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
8. Genencor Launches First Ever Commercial Enzyme Product for Cellulosic Ethanol
9. Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia
10. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
11. Product Development Timelines and Commercialization Strategy Are Focus of New Group at Premier Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ... as changes to Martine Rothblatt , Ph.D,s compensation ... United Therapeutics announced the promotion of Roger ... and David Zaccardelli , Pharm.D. to Executive Vice ... promotions, Dr. Rothblatt,s title will change from Chairman and ...
(Date:12/17/2014)... 2014   Synageva BioPharma Corp. (NASDAQ: ... for rare disorders, announced today its presentation at the ... San Francisco, CA. ... will present on Monday, January 12, 2015, at 9:00 ... webcast live and may be accessed from the "Webcasts ...
(Date:12/15/2014)... 15, 2014 Organovo Holdings, Inc. (NYSE ... on delivering breakthrough 3D bioprinting technology,  today celebrated ... of its exVive3D TM Human Liver Tissue.  ... full commercial release on November 18, has been ... several awards for innovation. Most recently, ...
(Date:12/15/2014)... COPENHAGEN, Denmark , Dec. 15, 2014 /PRNewswire/ ... its innovative TransCon technology to address significant unmet ... from its ongoing Phase 2 pediatric study to ... growth hormone deficiency, or GHD.  This interim analysis ... the anticipated total enrollment in the study, completing ...
Breaking Biology Technology:United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4
... -- China-Biotics, Inc.,(Nasdaq: CHBT ) ("China-Biotics", "the Company"), ... and,distribution of probiotics products, today announced its financial results for,the ... 2009. , , First Quarter 2010 Highlights, ... $15.4 million, -- Gross profit rose 34.5% ...
... , QUEBEC CITY, Aug. 17 /PRNewswire-FirstCall/ - AEterna Zentaris ... "Company"), a global biopharmaceutical company focused on endocrine therapy ... North American efficacy trial Z-033 and the safety trial ... endocrinology compound for urology, cetrorelix pamoate. As announced on ...
... the safety of their drinking water for granted, that ordinary ... Katzir of Tel Aviv University,s School of Physics and Astronomy. ... spillage, natural disaster or sabotage, the physicist has developed a ... community,s water supply in real time. Modifying special ...
Cached Biology Technology:China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 2China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 3China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 4China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 5China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 6China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 7China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 8China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 9China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 10China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 11AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 3AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 4AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 5AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 6AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 7Monitoring water through a snake's eyes 2Monitoring water through a snake's eyes 3
(Date:12/10/2014)... RALEIGH, N.C. , Dec. 9, 2014  Valencell, ... announced it is seeing a staggering demand from its ... demand, the Company revealed, is not solely coming from ... industries as well. "A wearable is only ... a result, accuracy is the ultimate driver in long-term ...
(Date:12/5/2014)... Dec. 4, 2014 Increased emphasis on ... in new testing and inspection technologies. The convergence ... to a range of innovative test solutions. This ... Generation Y, which is generally more inclined towards ... product development strategies of test equipment vendors will ...
(Date:11/21/2014)... -- According to a new market research ... Access Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), ... Geography - Global Forecasts to 2020", published by MarketsandMarkets, ... around $25 Billion in 2014 and is expected to ... of 8.69%. Browse 116 market data Tables ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... clumps of protein found within nerve cells are ... were first identified in the early 1900s by German ... in a protein called tau cause it to aggregate ... Normally, the tau protein is involved in the formation ...
... in the mainland United States known for its tropical smell now ... house ants - so called because they tend to invade houses ... to Hawaii. And, according to Purdue University entomologist Grzegorz Buczkowski, it ... "Odorous house ants in Hawaii are not like they are ...
... Mich. Discovering new treatments and battling dangerous infections ... targeting the genetic disorder cystic fibrosis with projects funded ... studies, with support from a $110,000 grant from Hunt ... Translational Sciences Institute, expand the relationship between the two ...
Cached Biology News:Chemical engineers help decipher mystery of neurofibrillary tangle formation in Alzheimer's brains 2Pesky ants found in Hawaii demonstrate invasive characteristics 24 projects target cystic fibrosis with Hunt for a Cure funds 2
... antibody raised against a partial ... Immunogen: SF3B2 (NP_006833, 592 ... recombinant protein with GST tag. ... NM_006842 ...
...
Mouse monoclonal antibody raised against a partial recombinant ZNF155. NCBI Entrez Gene ID = ZNF155...
Mouse polyclonal antibody raised against a partial recombinant COASY. NCBI Entrez Gene ID = 80347...
Biology Products: